NCT06134193 2023-11-18
Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
Clinical Trials
11 trialsNCT06013943 2023-09-15
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
Eastern Hepatobiliary Surgery Hospital
Phase 2 Unknown
NCT04211168 2023-03-29
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05620498 2022-11-17
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04333927 2020-06-23
ACCORD
Sun Yat-sen University
Phase 2 Unknown
NCT03772132 2018-12-11
Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT03768375 2018-12-07
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT00003296 2013-12-19
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01317069 2011-03-17
A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer
Simcere Pharmaceutical Co., Ltd
Phase 2 Unknown
NCT00356161 2006-07-25
HAI Via Interventionally Implanted Port Catheter Systems
Charite University, Berlin, Germany
Phase 2 Unknown